Insider Transactions Reported | C4 Therapeutics(CCCC)saw insider trading activity on 7/2/2025
ByAinvest
Wednesday, Jul 2, 2025 6:00 pm ET1min read
CCCC--
C4 Therapeutics(CCCC) saw insider trading activity on 7/2/2025, there were 2 insider trades during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 7/2/2025 | -- | Anderson Kenneth Carl、GROGAN DONNA ROY | Buy | 17225 | 1.51 | 26.01k |
| 4/3/2025 | -- | Anderson Kenneth Carl、GROGAN DONNA ROY | Buy | 17422 | 1.44 | 25.0k |
| 2/18/2025 | Chief Legal Officer | Siegel Jolie | Sell | 2914 | 3.18 | 9.27k |
| 2/18/2025 | Chief Business Officer | Boyle Scott N | Sell | 2368 | 3.18 | 7.53k |
| 2/18/2025 | Chief Financial Officer | Adams Kendra | Sell | 1863 | 3.20 | 5.96k |
| 2/18/2025 | Chief Financial Officer | Adams Kendra | Sell | 4559 | 3.18 | 14.5k |
| 2/18/2025 | Chief Accounting Officer | Mossler Mark | Sell | 1586 | 3.18 | 5.04k |
| 2/18/2025 | President & CEO | Hirsch Andrew | Sell | 22217 | 3.18 | 70.65k |
| 2/18/2025 | Chief Business Officer | Boyle Scott N | Sell | 1159 | 3.15 | 3.65k |
| 2/18/2025 | Chief Business Officer | Boyle Scott N | Sell | 1735 | 3.20 | 5.55k |
[Company Profile]
C4 Therapeutics, Inc. was incorporated in Delaware on October 7, 2015. The company is a biopharmaceutical company focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet